Pembina Agrees to Acquire Enbridge's Interests in Joint Ventures
By Stephen Nakrosis
Pembina Pipeline on Wednesday said it agreed to acquire Enbridge's interests in three joint ventures operated by the companies.
Pembina said the deal would see it acquire all Enbridge's interests in the Alliance, Aux Sable and NRGreen joint ventures for an aggregate purchase price of about C$3.1 billion ($2.3 billion), which includes approximately C$327 million of assumed debt. Pembina said it will finance the cash portion of the deal with net proceeds of a C$1.1 billion bought deal offering of subscription receipts, as well as funds drawn from existing credit facilities and cash on hand.
Once the deal closes, Pembina said, it will hold 100% of the equity interests in Alliance, Aux Sable's Canadian operations and NRGreen and about 85.4% of Aux Sable's U.S. operations. Pembina will also become the operator of all Alliance, Aux Sable and NRGreen businesses.
Enbridge said proceeds from the sale will be used to fund "strategic U.S. gas utilities acquisitions," and for debt reduction.
The Alliance JV transports natural gas sourced in Canada and the U.S. to Chicago, while Aux Sable operates NGL extraction and fractionation facilities in both countries, Enbridge said. NRGreen operates waste heat recovery facilities along the Alliance Pipeline, according to Enbridge.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 13, 2023 17:48 ET (22:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks